The mRNA vaccine giant will launch 34 vaccine projects

As we all know, As an mRNA vaccine giant, Moderna has total revenue of $18.

Among them, the new crown vaccine Spikevax (mRNA-1273) sold more than 800 million doses in 2021 and generated revenue of $

Moderna's R&D pipeline spans a variety of areas, including COVID-19 vaccines, influenza vaccines, preventive vaccines, system secretion and cell surface therapy; Exploratory areas include tumor vaccines, local regenerative therapies, and cell therapies

In 2023-2026, Moderna expects to launch a variety of vaccines worldwide, including human respiratory syncytial virus (RSV) vaccines and influenza vaccines, COVID-19 vaccines, and mRNA vaccines

On Thursday, Moderna showcased the company's clinical programs for multiple indications, including 34 vaccines under development

Moderna said it will continue to invest in its manufacturing capacity to support vaccine production

1 Rare disease

Because of the potential of mRNA technology, Moderna will use it for rare disease research

For propionic acidemia (PA), the company is developing a drug, mRNA-3927, that encodes the key enzyme that patients are missing, propionyl-CoA carboxylase, thereby alleviating metabolic abnormalities

For methylmalonic acidemia (MMA), the company has included the first two groups of patients in phase I/II studies to evaluate the safety and pharmacology

For glycogen storage disease type I.

Moderna is also advancing a new drug candidate, mRNA-3139, for the treatment

2 Respiratory vaccines

Moderna's COVID-19 vaccine has been a huge success

Moderna has introduced two COVID-19 vaccine enhancers to meet different market needs: mRNA-1273.

mRNA-1273.

The company's influenza vaccine candidate, mRNA-1010, is in phase III clinical development in the southern hemisphere, with approximately 6,000 patients involved

There is currently no mature RSV vaccine
for clinical application.
In Respiratory Syncytial Virus (RSV), Moderna initiated a Phase III trial that will evaluate the efficacy of mRNA-1345 in older people aged 60 years and older
.
To date, the test has recruited more than 24,000 patients
.
34,000 patients are expected to participate in the trial
.
In addition to the elderly, RSV is also a virus
of concern to young children.
Moderna also conducted a Phase I trial in children to assess the effects
of mRNA-1345.

In addition to the single-dose vaccine, Moderna is advancing several respiratory infection bacterial combination vaccines, including a Phase I/II trial on mRNA-1073 to test its effects on
COVID-19 and influenza.
The company is also working on mRNA-1230, a candidate vaccine for COVID-19, influenza and RSV, and is expected to launch clinical trials
this year.

3 CMV and cancer vaccines

Moderna is developing a cytomegalovirus (CMV) vaccine, and the company is evaluating a phase III trial of mRNA-1647 designed to prevent congenital CMV, and recruitment for this study is ongoing
.

Moderna is also developing personalized cancer vaccines, including mRNA-4157, which are used in conjunction with Merck's Keytruda for trial evaluation
in patients with resected melanoma at high risk of recurrence.
The combination therapy study is still in Phase II clinical trials and is expected to receive first-hand data
by the end of the fourth quarter of this year.

It seems that Moderna's mRNA vaccine is not only limited to the new crown, but can even be used in the
treatment of tumors and various diseases.

Resources: